Flowonix Medical focuses on advanced implantable drug-delivery solutions, centered on its Prometra II Programmable Infusion Pump System. The company said it will use the proceeds to further investment in sales and marketing infrastructure to support the continued commercial ramp of Prometra II and to expand manufacturing capacity. Flowonix received FDA approval to market the Prometra system in 2012 after conducting its first clinical trial in 2007. Founded in 2005 and led by President and CEO Larry Heaton, the company aims to improve care for patients with chronic pain via implantable drug delivery. The recent financing includes both an equity-style investment and venture term debt, reflecting a mix of capital sources. The company is headquartered in Mount Olive, New Jersey. Flowonix Medical Inc. is a medical device company focused on advanced, implantable drug-delivery solutions, centered on the Prometra Programmable Infusion Pump System. Prometra received FDA marketing approval in 2012 after clinical trials, and the company emphasizes the device's accuracy, longevity and safety for chronic pain treatment. Flowonix plans to use new capital to invest in sales and marketing infrastructure, build and mobilize sales and support teams, and pursue new product development. It also intends to broaden the addressable market to include cancer pain patients and those who fail other implantable treatments. Founded in 2005, Flowonix has offices in New Jersey and Massachusetts and holds multiple patents related to its implantable pump technology. Flowonix Medical develops implantable drug-delivery solutions, notably Prometra, an FDA-approved pump that delivers therapeutic drugs into the spine to treat chronic disorders. The company is focused primarily on alleviating chronic pain. Flowonix intends to use new capital to enter the U.S. market and to continue developing its drug delivery technologies. Founded in 2005 and based in Mt. Olive, New Jersey, the company is led by President and CEO Steve Adler. It recently received FDA approval to market Prometra, positioning the company for commercial expansion. The company raised $25M in funding to support these efforts.

Total raised

$81M

Funding rounds

6

Latest round

Debt Financing

Latest activity

Jun 2016